Magna

Glimepiride, the active ingredient in Magna, is a second‑generation sulfonylurea presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients by enhancing insulin secretion. GNH USA supplies Magna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Glimepiride is used in the management of type 2 diabetes mellitus, acting on pancreatic beta‑cells to improve glycaemic control. - Type 2 diabetes mellitus: lowers blood glucose by stimulating insulin release. - Adults inadequately controlled with diet and exercise: provides additional glucose‑lowering effect. - Combination therapy with metformin: offers complementary mechanisms to achieve target HbA1c.

Glimepiride may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypoglycaemia: episodes of low blood sugar, especially with missed meals. - Weight gain: modest increase in body weight. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Abdominal discomfort: mild stomach pain or bloating.

Serious or Rare Side Effects: - Severe hypoglycaemia: prolonged low glucose requiring medical attention. - Allergic reactions: rash, pruritus, or angioedema. - Stevens‑Johnson syndrome: rare severe skin reaction. - Hemolytic anaemia: destruction of red blood cells. - Liver dysfunction: elevated transaminases or hepatitis. - Pancreatitis: inflammation of the pancreas.

When prescribing or dispensing Glimepiride, consider the following safety measures. - Blood‑glucose monitoring: regularly check fasting and post‑prandial glucose levels. - Renal impairment: adjust dose or avoid use in severe kidney disease. - Hepatic impairment: use with caution in patients with liver dysfunction. - Sulfonylurea allergy: contraindicated in individuals with known hypersensitivity. - Elderly patients: start at the lowest effective dose and monitor closely. - Store at ambient temperature: keep in the original container, protect from moisture.

Glimepiride can interact with several drug classes, affecting its efficacy or safety.

Major Interactions (Avoid): - Other sulfonylureas: additive hypoglycaemic effect. - Meglitinides: increased risk of severe hypoglycaemia. - Strong CYP2C9 inhibitors (e.g., fluconazole): raise glimepiride plasma levels. - MAO inhibitors: potential for unpredictable glucose control. - Insulin: may cause profound hypoglycaemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Thiazide diuretics: can enhance hypoglycaemic response. - ACE inhibitors: may affect renal clearance. - NSAIDs: possible alteration of glucose metabolism. - Oral contraceptives: may modify plasma concentrations.